Feds Approve Large-Scale Weed Making for Clinical Trials
Published Date: 2/13/2026
Notice
Summary
Scottsdale Research Institute wants to make large amounts of marijuana and related substances for clinical trials and customers. People who already make or use these drugs can comment or ask for a hearing by April 14, 2026. This move could speed up research and distribution, but no other drug activities are allowed under this registration.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Application to Bulk Manufacture Schedule I Cannabis
Scottsdale Research Institute applied on January 8, 2026 to be registered as a bulk manufacturer of Marihuana Extract (code 7350), Marihuana (code 7360), and Tetrahydrocannabinols (code 7370), all listed in Schedule I. The company says it plans to bulk manufacture those substances to support clinical trials and to distribute to its customers.
Comment and Hearing Deadline for Stakeholders
Registered bulk manufacturers of the affected basic classes and applicants may submit electronic comments or objections, and may file a written request for a hearing, on or before April 14, 2026. Comments must be submitted through https://www.regulations.gov and submitters will receive a Comment Tracking Number.
Registration Limited to Manufacturing Only
The notice states that no other activities for the listed drug codes are authorized under this registration. If registered, Scottsdale Research Institute would only be authorized for bulk manufacture of the listed substances.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2026-02907, Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases
The National Cancer Institute plans to give Kyverna Therapeutics an exclusive license to use a special CAR therapy that helps treat or prevent autoimmune diseases caused by B cells. This means Kyverna will be the only company allowed to develop and sell this innovative treatment. If you want to comment or apply for a license, you need to act by March 2, 2026.
Next: 2026-02909, Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to make large amounts of psilocybin and psilocyn, two powerful research drugs, to help with their studies and clinical trials. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 14, 2026. This move could speed up important medical research while keeping safety rules in check.